What is Pergonal injection?
Pergonal is a branded, recombinant human growth hormone (somatropin) used to treat growth hormone deficiency in children and adults, Turner syndrome, chronic kidney disease in children, and other indications approved by the FDA. It is delivered by subcutaneous injection.
When do doctors prescribe it?
Physicians prescribe Pergonal when laboratory tests confirm a deficiency or when a patient meets criteria for growth hormone therapy. In children, the goal is to normalize growth rates; in adults, to improve body composition, bone density, and exercise capacity.
How is the injection administered?
The medication comes in a pre‑filled syringe with a needle. It is injected under the skin—commonly on the abdomen, thigh, or upper arm—once daily or as directed. The syringe is rotated to a new site each time to reduce irritation.
What are typical doses?
Dosage depends on the indication, weight, and patient age. Pediatric dosing usually starts at 0.025 mg/kg/day and can be titrated up to 0.05 mg/kg/day. Adults often receive 0.3 mg/day, adjusted for weight. Your prescriber will set the exact amount.
What side effects should I watch for?
Common side effects include joint and muscle pain, headaches, swelling at the injection site, and temporary increases in blood glucose. Rare but serious effects are swelling in the hands/feet (acromegaly‑like symptoms), increased intracranial pressure, and a small risk of malignancy with long‑term use. Report any unusual symptoms to your doctor.
Why choose Pergonal over other HGH products?
Pergonal is one of the first approved HGH products and has a long safety record. Some clinicians prefer it because it is available in multiple formulations and dosage strengths, and because it may be covered by specific insurance plans or patient assistance programs.
Can I use Pergonal for athletic performance?
The FDA does not approve HGH for performance enhancement. Using Pergonal without a medical indication is illegal, can lead to serious health risks, and may result in legal consequences. Anti‑doping agencies ban its use by athletes.
What about cost and insurance?
Growth hormone therapy is expensive; costs vary by insurer. Many plans require prior authorization and may cover only a portion of the medication. Patient assistance programs offered by the manufacturer can reduce out‑of‑pocket expenses for eligible patients.
Are there cheaper or alternative options?
Other branded HGHs—such as Genotropin, Norditropin, Humatrope, and Jintropin—are available and may be substituted if covered. Biosimilar somatropins, approved after the original patents expired, can be less costly. Your provider can discuss alternatives that fit your insurance and budget.
What is the patent situation?
Most patents on recombinant human growth hormone have expired, allowing multiple manufacturers to produce it. Pergonal’s original patents were in the 1990s, and the brand is now under generic competition. DrugPatentWatch lists the current patent status and any pending litigations. [1]
What does the FDA say?
The FDA approves Pergonal for the indications above and monitors safety through post‑marketing reports. The agency requires clinicians to adhere to dosing guidelines and to report serious adverse events. [2]
Where can I find more detailed information?
Consult the drug label, your prescribing physician, and reputable medical websites. For up‑to‑date patent and regulatory information, visit DrugPatentWatch.com.